Crispino JD - Search Results

1

The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.

Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. Lee P, et al. Among authors: crispino jd. Leukemia. 2016 Sep;30(9):1816-23. doi: 10.1038/leu.2016.164. Epub 2016 Jun 10. Leukemia. 2016. PMID: 27285583 Free PMC article. Review.

2

Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.

Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mundschau G, et al. Among authors: crispino jd. Blood. 2003 Jun 1;101(11):4298-300. doi: 10.1182/blood-2002-12-3904. Epub 2003 Jan 30. Blood. 2003. PMID: 12560215 Free article.

3

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.

Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD. Greene ME, et al. Among authors: crispino jd. Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6. doi: 10.1016/j.bcmd.2003.08.001. Blood Cells Mol Dis. 2003. PMID: 14636651

4

GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.

Crispino JD. Crispino JD. Pediatr Blood Cancer. 2005 Jan;44(1):40-4. doi: 10.1002/pbc.20066. Pediatr Blood Cancer. 2005. PMID: 15390312 Review.

5

Transcription factor GATA-1 and Down syndrome leukemogenesis.

Muntean AG, Ge Y, Taub JW, Crispino JD. Muntean AG, et al. Among authors: crispino jd. Leuk Lymphoma. 2006 Jun;47(6):986-97. doi: 10.1080/10428190500485810. Leuk Lymphoma. 2006. PMID: 16840187 Review.

6

Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.

Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD. Kirsammer G, et al. Among authors: crispino jd. Blood. 2008 Jan 15;111(2):767-75. doi: 10.1182/blood-2007-04-085670. Epub 2007 Sep 27. Blood. 2008. PMID: 17901249 Free PMC article.

7

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Malinge S, Izraeli S, Crispino JD. Malinge S, et al. Among authors: crispino jd. Blood. 2009 Mar 19;113(12):2619-28. doi: 10.1182/blood-2008-11-163501. Epub 2009 Jan 12. Blood. 2009. PMID: 19139078 Free PMC article. Review.

8

Overexpression of survivin initiates hematologic malignancies in vivo.

Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Small S, et al. Among authors: crispino jd. Leukemia. 2010 Nov;24(11):1920-6. doi: 10.1038/leu.2010.198. Epub 2010 Sep 30. Leukemia. 2010. PMID: 20882051 Free PMC article.

9

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.

Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Park E, et al. Blood. 2011 Aug 25;118(8):2191-9. doi: 10.1182/blood-2011-04-351239. Epub 2011 Jun 28. Blood. 2011. PMID: 21715311 Free PMC article.

10

Myeloid leukemia in Down syndrome.

Khan I, Malinge S, Crispino J. Khan I, et al. Crit Rev Oncog. 2011;16(1-2):25-36. doi: 10.1615/critrevoncog.v16.i1-2.40. Crit Rev Oncog. 2011. PMID: 22150305 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

170 results

Search Page